Quarterly Report II 22/23
September 2022 – February 2023, Diamyd Medical AB (publ), Fiscal year 2022/2023Precision Medicine for Autoimmune Diabetes in Pivotal Phase 3Diamyd Medical’s B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B.Further information is available on https://www.diamyd.com
September 1, 2022 – February 28, 2023
· Net result: MSEK -57.9 (-46.5), second quarter: MSEK -25.0 (-9.0). · Result per share: SEK -0.8 (-0.6), second quarter: SEK -0.3 (-0.1) · Cash flow from operating activities: MSEK -52.4 (-18.2), second quarter: MSEK -25.4 (-18.6) · Cash and
